Sanofi Terminates Late-stage Trial for Rare Neurological Disorder Treatment; 2026 Guidance Maintained
Sanofi (SAN.PA) confirmed its full-year 2026 outlook after announcing its decision to discontinue a late-stage clinical study of riliprubart in chronic inflammatory demyelinating polyneuropathy.The French drugmaker said Tuesday it does not expect "any significant financial cost" from the termination of its Mobilize phase 3 study. For 2026, the company expects high single-digit sales growth at constant exchange rates, with constant-currency business EPS projected to outpace sales prior to share buybacks.The study was evaluating riliprubart in patients with the rare neurological condition who are refractory to standard-of-care treatment. An independent data monitoring committee triggered the shutdown after its interim analysis found that the trial was "unlikely to provide sufficient efficacy."However, Sanofi noted that the data revealed no safety issues. The company added that it plans to assess the remaining studies for riliprubart, including a late-stage Vitalize study in patients receiving intravenous immunoglobulin therapy."Sanofi will work closely with investigators and site teams to ensure a wind-down of the MOBILIZE study, with appropriate transition of care for all enrolled patients. Sanofi will conduct a thorough analysis of the MOBILIZE data to inform future research directions and contribute to the broader scientific understanding of CIDP," the company said in its press release.Sanofi's Paris-listed stock was down 1% by Wednesday midday trade.
